A test to gauge recurrence risk for kidney cancer is unable to predict which patients will benefit from adjuvant therapy

An American company called Genomic Health has been collaborating with Pfizer over the past 10 years to develop a 16-gene expression test to determine the chances of recurrence of kidney cancer after surgery. The test was validated in a study, which was published in The Lancet Oncology in 2015. The validation study showed that the […]

read more

16-gene recurrence score for high-risk kidney cancer offers prognostic value

Results from a phase III trial presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting held in Chicago last week confirmed the prognostic value of a 16-gene recurrence score (RS) in patients with high-risk renal cell carcinoma (RCC) undergoing adjuvant sunitinib therapy. Though the score cannot yet be used to select patients […]

read more

Potential molecular scoring method for predicting survival in metastatic kidney cancer

A recent study presented at the American Urology Association (AUA) Annual Meeting in Boston last month, described a new molecular (genetic) scoring method that could be used to predict survival in people with metastatic kidney cancer. There has been rapid adoption by researchers of using sets of genes, proteins, genetic variants or other variables (molecular signatures) […]

read more
Showing all 3 results